These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2559040)

  • 21. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender.
    Indridason OS; Pieper CF; Quarles LD
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3860-6. PubMed ID: 9814459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of FGF23 response to acute changes in serum calcium and PTH in humans.
    Wesseling-Perry K; Wang H; Elashoff R; Gales B; Jüppner H; Salusky IB
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1951-6. PubMed ID: 25062462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.
    Lorenzo V; Martín M; Rufino M; Jiménez A; Malo AM; Sanchez E; Hernández D; Rodríguez M; Torres A
    Am J Kidney Dis; 2001 Jun; 37(6):1260-6. PubMed ID: 11382697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation between Calcium, Phosphorus, Calcium-Phosphorus Index and iPTH in Chronic Kidney Disease Patients.
    Adhikary LP; Yadava SK; Pokharel A; Khadka D; Thakur R
    J Nepal Health Res Counc; 2015; 13(29):50-3. PubMed ID: 26411713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis.
    Rudnicki M; Frølich A; Haaber A; Tvedegaard E; Thode J
    Clin Nephrol; 1993 Oct; 40(4):225-9. PubMed ID: 8261680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of reduced dialysate calcium on mineral metabolism in hemodialysis patients].
    Fujimori A; Yorifuji M; Sakai M; Fukagawa M
    Clin Calcium; 2005 Sep; 15 Suppl 1():121-4; discussion 124. PubMed ID: 16272643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis.
    Levitt H; Smith KG; Rosner MH
    Hemodial Int; 2009 Oct; 13(4):518-25. PubMed ID: 19758299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of 1-84 PTH measurement in relation to bone alkaline phosphatase and bone Gla protein in hemodialysis patients.
    Miwa N; Nitta K; Kimata N; Watanabe Y; Suzuki K; Kawashima A; Haga M; Watanabe R; Aoki T; Akiba T; Nihei H
    Nephron Clin Pract; 2003; 94(2):c29-32. PubMed ID: 12845234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction of metabolic acidosis in hemodialysis: consequences on serum leptin and mineral metabolism.
    Bales AM; Moysés RM; dos Reis LM; Graciolli FG; Hung J; Martins Castro MC; Elias RM
    Int Urol Nephrol; 2015 Jan; 47(1):177-82. PubMed ID: 25252843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.
    Tzanakis IP; Papadaki AN; Wei M; Kagia S; Spadidakis VV; Kallivretakis NE; Oreopoulos DG
    Int Urol Nephrol; 2008; 40(1):193-201. PubMed ID: 18193489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.